Smoking cessation at the pharmacy: feasibility and benefits based on a French observational study with six-month follow-up

Figures & data

Table 1 Study parameters measured by study visits

Study visits	V0	V1	V2	V3	V4
Time of visits	At inclusion	At 1 month	At 2 months	At 3 months	At 6 months
Subjects attending visits	n=227 (100%)	n=132 (58.1%)	n=88 (38.8%)	n=65 (28.6%)	n=53 (23.3%)
Demographic information
Age, mean±SD (n)	45.5±13.6 (227)
Sex (female), % (n)	64.3 (227)
Cigarette consumption, %
1–10 cig/d	17
11–22 cig/d	56
21–30 cig/d	22
>30 cig/d	5
At least one possible smoking-related illness, %	75
Fagerström score (out of 10), mean±SD	4.96±2.37
Motivation to quit smoking (VAS 0–10), mean±SD	7.3±2.2
NRT users, %	96.9	86.4	84.1	69.2	45.3
Duration of the interview (minutes), mean±SD	n=222	n=129	n=83	n=62	n=49
Average duration	29.7±13.1	22.4±9.9	20.5±7.3	22.9±9.6	20.7±9.1
Main topic selected for the interview, %
Benefits of smoking cessation	37.2	26.6
Helping pregnant women to stop			20.7
Perceived risks of quitting				27.1	18.8
Quality of life: SF-12, mean±SD	n=226	n=130	n=86	n=64	n=51
Physical composite score	49.1±9.6	50.7±9.0	51.9±7.5	51.4±8.4	53.54±7.8
Mental composite score	42.6±10.8	46.1±10.5	47.5±10.4	49.4±9.2	48.96±11.5
SF-12 for the 53 completers, mean±SD	n=53	n=49	n=52	n=49	n=51
Physical composite score	48.0±10.3	51.4±9.8	52.0±8.4	52.0±8.2	53.5±7.8
Mental composite score	42.8±11.3	47.7±11.0	47.2±11.4	49.4±9.6	49.0±11.5
SCQoL subscores, mean±SD	n=226	n=130	n=87	n=64	n=51
Self-control	39.3±17.5	51.4±18.9	53.5±19.6	58.2±18.3	59.2±17.4
Anxiety	51.8±26.2	61.4±24.5	66.2±24.9	71.9±22.6	69.1±21.9
Social interactions	40.5±11.2	43.2±11.02	45.8±11.2	46.5±9.8	45.8±13.8
Sleep	52.4±16.8	53.30±17.1	55.41±15.7	53.8±15.8	57.6±18.4
Subject receptiveness (VAS 0–10), mean±SD		8.4±2.0	8.6±1.8	8.8±1.7	8.6±2.4
Questionnaire on smoking cessation
Number of cigarettes per day, mean±SD		4.3±6.4	3.3±5.5	2.5±5.0	1.4±3.6
Weight gain since the last visit, % of yes		33.6	45.5	40.0	49.1
Participant satisfaction (CSQ8), mean±SD				n=65	n=53
Global score (out of 4)				3.6±0.4	3.7±0.4
Pharmacist satisfaction (VAS 0=not at all, 10=very useful), mean±SD					n=20
“Is the STOP study useful to my pharmaceutical practice?”					8.1±1.5
“Is the STOP study adapted to my pharmaceutical practice?”					7.5±1.2
“Is the STOP study adapted to my clients?”					7.1±1.2

Abbreviations: VAS, visual analog scale; NRT, nicotine replacement therapy; SF-12, Short Form 12; SCQoL, Smoking Cessation Quality of Life; CSQ8, Client Satisfaction Questionnaire; STOP, Sevrage Tabagique à l’Officine: Smoking Cessation Program at the Pharmacy.

Figure 1 Number of participants present and number using nicotine replacement therapy at each visit.

Abbreviations: NRT, nicotine replacement therapy; V0, inclusion visit; V1, visit at 1 month; V2, visit at 2 months; V3, visit at 3 months; V4, visit at 6 months.

Table 2 Participant flow and reasons for withdrawal (several reasons were possible)

Number of patients present at visit	Withdrawal period	Withdrawal with no indicated reason	Wishes to stop the visits	Lost to follow-up	Relapse	Smokingcessation	Did not meet inclusion criteria	Comments
V0=227
V1=132	V0–V1	54	24	8	2	1	1	5 not present at V1 but present at V2
V2=88	V1–V2	32	4	2	6	4		1 not present at V2 but present at V3
V3=65	V2–V3	11	3	2	3	4		3 not present at V3 but present at V4
V4=53	V3–V4	12	1	1		1

Abbreviations: V0, inclusion visit; V1, visit at 1 month; V2, visit at 2 months; V3, visit at 3 months; V4, visit at 6 months.

Figure 2 SF12 physical and mental health composite scores.

Abbreviations: SF-12, Short Form 12; min, minimum; max, maximum; V0, inclusion visit; V1, visit at 1 month; V2, visit at 2 months; V3, visit at 3 months; V4, visit at 6 months.